| Literature DB >> 31350457 |
Jingyan Song1,2, Xiaoming Wang2, Ying Guo1, Yi Yang2, Kaiyue Xu2, Tianqi Wang2, Yuanhong Sa2, Lihua Yuan2, Huaying Jiang2, Jiayin Guo3, Zhengao Sun4,5.
Abstract
The complexity of follicular fluid metabolome presents a significant challenge for qualitative and quantitative metabolite profiling, and for discovering the comprehensive biomarkers. In order to address this challenge, a novel SWATHtoMRM metabolomics method was used for providing broad coverage and excellent quantitative capability to discover the human follicular fluid metabolites related to recurrent spontaneous abortion (RSA) after in vitro fertilization and embryo transfer, and to evaluate their relationship with pregnancy outcome. The follicular fluid samples from the spontaneous abortion group (n = 22) and the control group (n = 22) were analyzed using ultra-performance liquid chromatography high-resolution mass spectrometry. A novel, high-coverage, targeted metabolomics method (SWATH to MRM) and a targeted metabolomics method were used to find and validate the differential metabolites between the two groups. A total of 18 follicular fluid metabolites, including amino acids, cholesterol, vitamins, fatty acids, cholic acid, lysophosphatidylcholine and other metabolites, were identified. In the RSA group, 8 metabolites, namely dehydroepiandrosterone, lysoPC(16:0), lysoPC(18:2), lysoPC(18:1), lysoPC(18:0), lysoPC(20:5), lysoPC(20:4), and lysoPC(20:3), were up-regulated, and 10 metabolites, namely phenylalanine, linoleate, oleic acid, docosahexaenoic acid, lithocholic acid, 25-hydroxyvitamin D3, hydroxycholesterol, 13-hydroxy-alpha-tocopherol, leucine, and tryptophan, were down-regulated. These differential metabolites related to RSA may provide a possible diagnostic basis and therapeutic target for RSA, as well as a scientific basis for elucidating the mechanism of RSA.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31350457 PMCID: PMC6659694 DOI: 10.1038/s41598-019-47370-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The clinical background of control group and RSA group.
| Clinical parameter | Control group | RSA group | T-test ( |
|---|---|---|---|
| Age (years) | 30.3 ± 3.5 | 29.7 ± 3.8 |
|
| Infertility duration (years) | 3.5 ± 1.9 | 3.1 ± 2.2 |
|
| Body mass index (kg/m2) | 21.7 ± 1.1 | 21.6 ± 1.2 |
|
| Miscarriage history (years) | 3.5 ± 1.3 | 3.2 ± 1.0 |
|
| Number of spontaneous abortions (N) | 0 | 2.8 ± 0.55 | < |
| Gestational age of abortion (weeks) | 9.3 ± 2.3 | 9.8 ± 2.2 |
|
| Basal FSH (mIU/mL) | 6.8 ± 1.6 | 6.8 ± 1.9 |
|
| Basal E2 (pg/mL) | 46.8 ± 3.1 | 46.6 ± 3.7 |
|
| Basal AFC (N) | 15.8 ± 6.0 | 15.3 ± 5.1 |
|
| Duration of Gn (days) | 12.1 ± 2.4 | 12.1 ± 2.1 |
|
| Dosage of Gn (mg) | 2635.1 ± 987.3 | 2448.8 ± 828.1 |
|
| Retrieved oocytes (n) | 13.2 ± 3.5 | 12.2 ± 2.8 |
|
| Metaphase II oocytes (n) | 9.1 ± 2.3 | 8.9 ± 2.6 |
|
| Fertilization rate (n, %) |
| ||
| IVF | 13 (59.1%) | 14 (63.6%) | |
| ICSI | 9 (40.9%) | 8 (36.4%) | |
| Usable embryos (n) | 5.2 ± 2.8 | 4.5 ± 2.1 |
|
Figure 1The total ion chromatography of all follicular fluid samples in positive mode.
Figure 2The total ion chromatography of all follicular fluid samples in negative mode.
Figure 3The score plot of PCA analysis of all FF samples in positive mode.
Figure 4The score plot of PCA analysis of all FF samples in negative mode.
Figure 5The MS2 spectra and matching result of M15.
Characterization of the biomarkers between control group and RSA group in follicular fluid.
| Compound | TR (min) | m/z | Polarity | Metabolites | Fragment ions (m/z) |
|---|---|---|---|---|---|
| M1 | 2.8 | 164.0718 | − | Phenylalanine | 72, 103, 147 |
| M2 | 1.9 | 279.2310 | − | Linoleate | 197 |
| M3 | 3.2 | 281.2487 | − | Oleic acid | 263 |
| M4 | 8.6 | 327.2328 | − | Docosahexaenoic acid | 59, 135, 177, 229, 283 |
| M5 | 10.0 | 375.2908 | − | Lithocholic acid | 59, 283 |
| M6 | 5.1 | 287.2023 | − | Dehydroepiandrosterone | 97 |
| M7 | 9.0 | 399.3266 | − | 25-Hydroxyvitamin D3 | 355, 271, |
| M8 | 9.6 | 401.3418 | − | 25-Hydroxycholesterol | 321 |
| M9 | 9.5 | 491.3715 | − | 13-hydroxy-alpha-tocopherol | 445, 401 |
| M10 | 2.6 | 132.1029 | + | Leucine | 69, 86 |
| M11 | 3.2 | 205.0978 | + | Tryptophan | 118, 146, 188 |
| M12 | 6.3 | 494.3246 | − | LysoPC(16:0) | 86, 184, 240, 339 |
| M13 | 4.7 | 520.3394 | + | LysoPC(18:2) | 104, 184, 502 |
| M14 | 5.2 | 522.3553 | + | LysoPC(18:1) | 104, 184, 504 |
| M15 | 6.1 | 524.3710 | + | LysoPC(18:0) | 104, 184, 506 |
| M16 | 4.9 | 542.3237 | + | LysoPC(20:5) | 104, 146, 337, 483 |
| M17 | 5.6 | 544.3398 | + | LysoPC(20:4) | 104, 184, 485, 526 |
| M18 | 6.6 | 546.3547 | + | LysoPC(20:3) | 104, 184, 341, 487 |
The MRM parameters for targeted metabolomics method.
| Compound | Q1/Q3 | Dwell time (ms) | DP (V) | CE (eV) |
|---|---|---|---|---|
| Phenylalanine | 164/147 | 10 | −50 | −15 |
| 164/103 | 10 | −50 | −25 | |
| Linoleate | 279/197 | 10 | −50 | −25 |
| Oleic acid | 281/177 | 10 | −50 | −30 |
| 281/205 | 10 | −50 | −20 | |
| Docosahexaenoic acid | 327/283 | 10 | −50 | −20 |
| 327/229 | 10 | −50 | −35 | |
| Lithocholic acid | 357/313 | 10 | −50 | −20 |
| 357/259 | 10 | −50 | −28 | |
| Dehydroepiandrosterone | 367/287 | 10 | −50 | −25 |
| 367/97 | 10 | −50 | −40 | |
| 25-Hydroxyvitamin D3 | 445/427 | 10 | −50 | −25 |
| 445/401 | 10 | −50 | −35 | |
| 25-Hydroxycholesterol | 447/429 | 10 | −50 | −25 |
| 447/403 | 10 | −50 | −30 | |
| 13-hydroxy-alpha-tocopherol | 491/473 | 10 | −50 | −19 |
| 491/447 | 10 | −50 | −25 | |
| Leucine | 132/86 | 10 | 50 | 18 |
| 132/69 | 10 | 50 | 25 | |
| Tryptophan | 205/188 | 10 | 50 | 20 |
| 205/146 | 10 | 50 | 28 | |
| LysoPC(16:0) | 494/476 | 10 | −50 | −20 |
| 494/86 | 10 | −50 | −50 | |
| LysoPC(18:2) | 520/184 | 10 | 50 | 35 |
| 520/104 | 10 | 50 | 45 | |
| LysoPC(18:1) | 522/184 | 10 | 50 | 35 |
| 522/104 | 10 | 50 | 45 | |
| LysoPC(18:0) | 524/184 | 10 | 50 | 35 |
| 524 /104 | 10 | 50 | 45 | |
| LysoPC(20:5) | 542/184 | 10 | 50 | 35 |
| 542 /104 | 10 | 50 | 45 | |
| LysoPC(20:4) | 544/184 | 10 | 50 | 35 |
| 544/104 | 10 | 50 | 45 | |
| LysoPC(20:3) | 546/184 | 10 | 50 | 35 |
| 546/104 | 10 | 50 | 45 |
Statistical results between control group and RSA group in follicular fluid.
| Metabolites | Screening analysis | Targeted analysis | ||||
|---|---|---|---|---|---|---|
| T-test (p) | VIP | FDR | T-test (p) | VIP | FDR | |
| Phenylalanine | 0.0076 | 2.13 | 0.48% | 0.0009 | 1.89 | 0.08% |
| Linoleate | 0.0012 | 2.78 | 0.12% | 0.0028 | 1.44 | 0.02% |
| Oleic acid | 0.0004 | 1.73 | 0.61% | 0.0052 | 1.33 | 0.11% |
| Docosahexaenoic acid | 0.0031 | 3.94 | 0.04% | 0.0008 | 2.57 | 0.98% |
| Lithocholic acid | 0.0073 | 2.21 | 0.21% | 0.0081 | 2.16 | 0.32% |
| Dehydroepiandrosterone | 0.0042 | 1.82 | 0.09% | 0.0019 | 2.28 | 0.04% |
| 25-Hydroxyvitamin D3 | 0.0061 | 1.76 | 0.43% | 0.0017 | 1.46 | 0.33% |
| 25-Hydroxycholesterol | 0.0015 | 1.63 | 0.01% | 0.0069 | 1.45 | 0.31% |
| 13-hydroxy-alpha-tocopherol | 0.0020 | 1.71 | 0.02% | 0.0019 | 1.43 | 0.32% |
| Leucine | 0.0001 | 2.11 | 0.07% | 0.0022 | 1.62 | 0.15% |
| Tryptophan | 0.0002 | 2.64 | 0.002% | 0.0003 | 1.97 | 0.72% |
| LysoPC(16:0) | 0.0011 | 2.87 | 0.08% | 0.0073 | 2.03 | 0.08% |
| LysoPC(18:2) | 0.0015 | 1.89 | 0.11% | 0.0091 | 2.89 | 0.33% |
| LysoPC(18:1) | 0.0081 | 1.68 | 0.29% | 0.0068 | 1.47 | 0.09% |
| LysoPC(18:0) | 0.0064 | 1.77 | 0.20% | 0.0007 | 3.79 | 0.14% |
| LysoPC(20:5) | 0.0047 | 1.86 | 0.41% | 0.0023 | 1.72 | 0.02% |
| LysoPC(20:4) | 0.0026 | 2.67 | 0.06% | 0.0009 | 1.62 | 0.01% |
| LysoPC(20:3) | 0.0041 | 2.31 | 0.04% | 0.0012 | 1.63 | 0.09% |
VIP: Variable important in the projection; FDR: false discovery rate.
Figure 6Metabolite profiles of the 12 candidate biomarkers (M1-M12) obtained from the quantitative analysis of the subjects (p < 0.05).
Figure 7Metabolite profiles of the 6 candidate biomarkers (M13-M18) obtained from the quantitative analysis of the subjects (p < 0.05).